TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07794592: A Study Comparing Two Ways of Taking Olomorasib (LY3537982) in Healthy Participants

Sponsor: Eli Lilly and Company · Phase: PHASE1 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 24 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$5,802,032

Rescue Site Savings

+$3,837,920

Unlock Full NCT07794592 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07794592 Rescue Dossier →